Follicum (Lund, Sweden) is an early-stage biopharmaceutical company focusing on developing novel therapeutics for the management of hair growth. Unwanted hair loss and unwanted hair growth affects millions of men and women worldwide, and both markets pose huge commercial potential. Follicum’s products are expected to stimulate regrowth of the hair and formation of new hair follicles, which no other therapy can do today. However, it is also a possibility that Follicum’s technology could be used to inhibit hair growth on parts of the body where hair is cosmetically challenging. Follicum was listed on AktieTorget on Tuesday November 25th, 2014. For any information regarding Follicum AB, please visit the official website.